Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hikma Pharmaceuticals plc

https://www.hikma.com/

Latest From Hikma Pharmaceuticals plc

Amarin Steps Closer To EU Cardiovascular Risk Market

The European Medicines Agency has recommended in favor of approval for Amarin’s fish-oil derivative, Vazkepa.

Europe Approvals

Amarin Builds Sales Infrastructure For EU Vazkepa Launch

With an approval nod from the EMA’s scientific committee for its fish oil product Vazkepa, launch plans for the EU for this “multi-billion dollar” opportunity are on track, says Amarin CEO.

EU Approvals

Hikma Opens Discussions To Acquire GSK OTC, Rx Businesses In Egypt, Tunisia

With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.

Moment Of Truth In EU For Amarin’s ‘Multi-Billion-Dollar Opportunity’ Drug

The European Medicines Agency is expected to decide soon whether Amarin’s fish oil pill, Vascepa, should win pan-EU marketing approval for reducing cardiovascular risk.

Drug Review Cardiovascular
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • EIMC United Pharmaceuticals
    • Roxane Laboratories, Inc.
    • West-Ward Pharmaceuticals Corp.
UsernamePublicRestriction

Register